My watch list  


Systematic (IUPAC) name
CAS number 3424-98-4
ATC code N03AX17
PubChem 159269
Chemical data
Formula C10H14N2O5 
Mol. mass 242.23 g/mol
Synonyms 1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil
β-L-thymidine (LdT)
Pharmacokinetic data
Bioavailability  ?
Protein binding Low (3.3% in vitro)
Metabolism Nil
Half life 40 to 49 hours (terminal phase)
Excretion Renal
Therapeutic considerations
Licence data


Pregnancy cat.


Legal status


Routes Oral

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3]

Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken once daily.


  1. ^ Lai CL, Leung N, Teo EK, et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology 129 (2): 528–36. doi:10.1016/j.gastro.2005.05.053. PMID 16083710.
  2. ^ Lai CL, Gane E, Liaw YF, et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med 357 (25): 2576–88. doi:10.1056/NEJMoa066422. PMID 18094378.
  3. ^ Chan HL, Heathcote EJ, Marcellin P, et al (2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med 147 (11): 745–54. PMID 17909201.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Telbivudine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE